European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Garbe, Claus; Amaral, Teresa; Peris, Ketty; Hauschild, Axel; Arenberger, Petr; Basset-Séguin, Nicole; Bastholt, Lars; Bataille, Véronique; Marmol, Véronique Del; Dréno, Brigitte; Fargnoli, Maria Concetta; Forsea, Ana‐Maria; Grob, Jean‐Jacques; Höeller, Christoph; Kaufmann, Roland; Kelleners‐Smeets, Nicole W.J.; Lallas, Aimilios; Lebbe, Célèste; Lytvynenko, Bodhan; Malvehy, Josep; Moreno‐Ramírez, D.; Nathan, Paul; Pellacani, Giovanni; Saïag, Philippe; Stratigos, Alexander J.; Akkooi, A.C.J. van; Vieira, Ricardo; Zalaudek, Iris; Lorigan, Paul

doi:10.1016/j.ejca.2022.04.018

Cited by 139 publications

(160 citation statements)

References 195 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Melanoma is considered to bear one of the highest mutation frequencies, and, therefore, has vast tumor heterogeneity [ 48 , 49 ]. This impedes the response to the immune therapies and patients’ survival [ 6 , 7 , 49 ]. Bearing that in mind we investigated the effectiveness of CBD in different tumors we tested in various cell lines.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

Marzęda

Wróblewska-Łuczka

Drozd

et al. 2022

IJMS

View full text Add to dashboard Cite

The medical application of cannabidiol (CBD) has been gathering increasing attention in recent years. This non-psychotropic cannabis-derived compound possesses antiepileptic, antipsychotic, anti-inflammatory and anxiolytic properties. Recent studies report that it also exerts antineoplastic effects in multiple types of cancers, including melanoma. In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP). The effects of CBD on the viability of melanoma cells were measured by the MTT assay; cytotoxicity was determined in the LDH test and proliferation in the BrdU test. Moreover, the safety of CBD was tested in human keratinocytes (HaCaT) in LDH and MTT tests. Results indicate that CBD reduces the viability and proliferation of melanoma-malignant cells and exerts additive interactions with MTX. Unfortunately, CBD produced antagonistic interaction when combined with CDDP. CBD does not cause significant cytotoxicity in HaCaT cell line. In conclusion, CBD may be considered as a part of melanoma multi-drug therapy when combined with MTX. A special attention should be paid to the combination of CBD with CDDP due to the antagonistic interaction observed in the studied malignant melanoma cell lines.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Therefore, there is still a need for cheap and effective treatment alternatives in patients with melanoma. Despite various currently available drugs, therapeutic regimens and methods in the treatment of malignant melanoma, the choice of the most effective treatment option is still a challenging issue for clinicians [ 5 , 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

Marzęda

Wróblewska-Łuczka

Drozd

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…There is no approved drug for NRAS-mutant melanoma yet [ 6 ]. When facing triple wild-type melanoma, the only therapy option available is immunotherapy, represented by anti-programmed cell death protein 1 (PD-1) and/or anti-cytotoxic T cell antigen 4 (CTLA-4) antibodies [ 7 ]. Programmed death-ligand 1 (PD-L1) expression of tumoral cells and/or tumor-infiltrating immune cells is a pivotal requirement of anti- PD-1/PD-L1 treatment for several cancer types.…”

Section: Introductionmentioning

confidence: 99%

Role of HMGB1 in Cutaneous Melanoma: State of the Art

Pomi

Borgia

Custurone

et al. 2022

IJMS

View full text Add to dashboard Cite

High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell metastasis development thanks to its ability to promote cell migration. This research aims to assess the role of this molecule in the pathogenesis of human melanoma and its potential therapeutic role. The research has been conducted on the PubMed database, and the resulting articles are sorted by year of publication, showing an increasing interest in the last five years. The results showed that HMGB1 plays a crucial role in the pathogenesis of skin cancer, prognosis, and therapeutical response to therapy. Traditional therapies target this molecule indirectly, but future perspectives could include the development of new target therapy against HMGB1, thus adding a new approach to the therapy, which has often shown primary and secondary resistance. This could add a new therapy arm which has to be prolonged and specific for each patient.

show abstract

“…Multidisciplinary experts have recently elaborated recommendations on treatment of melanoma, in which the first-line treatment of metastatic melanoma is target therapy or immune therapy [ 3 ]. The second-line treatment of melanoma is based on cytostatic drugs used in various combinations [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…The treatment results of melanoma after immunotherapy or molecularly targeted therapies are still unsatisfactory and the 5-year survival rate reaches less than 30% [ 2 ]. Therefore, new drugs or their combinations are constantly being tested against melanoma [ 3 ]. The aim of this study was to assess the influence of amantadine on human melanoma cells, both primary and metastatic, and check the anticancer impact of amantadine in combination with well-known chemotherapeutics like MTO and CDDP [ 20 , 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells

Krasowska

Gerkowicz

Wróblewska-Łuczka

et al. 2022

IJMS

View full text Add to dashboard Cite

Patients with Parkinson’s disease are prone to a higher incidence of melanoma. Amantadine (an anti-Parkinson drug) possesses the antiproliferative potential that can be favorable when combined with other chemotherapeutics. Cisplatin (CDDP) and mitoxantrone (MTO) are drugs used in melanoma chemotherapy, but they have many side effects. (1) Clinical observations revealed a high incidence of malignant melanoma in patients with Parkinson’s disease. Amantadine as an anti-Parkinson drug alleviates symptoms of Parkinson’s disease and theoretically, it should have anti-melanoma properties. (2) To characterize the interaction profile for combinations of amantadine with CDDP and MTO in four human melanoma cell lines (A375, SK-MEL 28, FM55P and FM55M2), type I isobolographic analysis was used in the MTT test. (3) Amantadine produces the anti-proliferative effects in various melanoma cell lines. Flow cytometry analysis indicated that amantadine induced apoptosis and G1/S phase cell cycle arrest. Western blotting analysis showed that amantadine markedly decreased cyclin-D1 protein levels and increased p21 levels. Additionally, amantadine significantly increased the Bax/Bcl-2 ratio. The combined application of amantadine with CDDP at the fixed-ratio of 1:1 exerted an additive interaction in the four studied cell lines in the MTT test. In contrast, the combination of amantadine with MTO (ratio of 1:1) produced synergistic interaction in the FM55M2 cell line in the MTT (* p < 0.05). The combination of amantadine with MTO was also additive in the remaining tested cell lines (A375, FM55P and SK-MEL28) in the MTT test. (4) Amantadine combined with MTO exerted the most desirable synergistic interaction, as assessed isobolographically. Additionally, the exposure of melanoma cell lines to amantadine in combination with CDDP or MTO augmented the induction of apoptosis mediated by amantadine alone.

show abstract

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

Cited by 139 publications

References 195 publications

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines—An Isobolographic Analysis

Role of HMGB1 in Cutaneous Melanoma: State of the Art

Anticancer Activity of Amantadine and Evaluation of Its Interactions with Selected Cytostatics in Relation to Human Melanoma Cells

Contact Info

Product

Resources

About